Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T19:25:16.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer now shows site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T20:28:37.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision number changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T20:43:35.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error instead of the usual study record content. This signals an access restriction or server issue impacting the NCT03528408 page.
    Difference
    19%
    Check dated 2026-09-19T21:51:16.000Z thumbnail image
  5. Check
    61 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.5 to v3.6.6, indicating a software revision of the site. This is a maintenance update and does not change the displayed study details or workflow.
    Difference
    0.1%
    Check dated 2026-08-29T19:43:56.000Z thumbnail image
  6. Check
    82 days ago
    Change Detected
    Summary
    Revision label on the page updated to v3.6.5, replacing the previous v3.6.4. This signals a minor update to the study record metadata rather than changes to study details.
    Difference
    0.1%
    Check dated 2026-08-08T18:25:37.000Z thumbnail image

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.